Labcorp Beats on Q3, Raises 2026 EPS Guidance to $18.30-$18.70
LH sits 37% above its 52-week low of $244.52.
Summary
Labcorp posted 6.9% revenue growth and 14.5% adjusted EPS growth in Q3 2026 and raised full-year adjusted EPS guidance to $18.30-$18.70, while signing a third acquisition (Millennium Health) and keeping $1.4 billion of buyback capacity.
Updates
· Reuters — Labcorp expects 2026 Biopharma Laboratory Services revenue growth of 7.4%-8.4% and Diagnostics Laboratories growth of 5.5%-6.2%.
- Q3 Revenue — Q3 revenue was $3.81 bln versus a consensus estimate of $3.76 bln, up 6.9% yr/yr.
- Q3 Earnings — Adjusted EPS from continuing operations was $4.78, up 14.5% yr/yr.
All 4 details
- Q3 Revenue Beat: actual $3.81 bln vs consensus estimate $3.76 bln (12 Analysts)
- Q3 adjusted EPS from continuing operations was $4.78.
- Q3 revenue rose 6.9% yr/yr
- Adjusted EPS for Q3 rose 14.5% yr/yr
Key Events · Earnings and Guidance · LH
-
Q3 Revenue Up 6.9% to $3.81B
Revenue rose to $3.81 billion from $3.56 billion, with organic growth of 5.5% and acquisitions net of divestitures adding 1.5%.
-
Adjusted EPS Up 14.5%, Guidance Raised
Adjusted EPS of $4.78 versus $4.18 a year ago; full-year 2026 adjusted EPS guidance lifted to $18.30-$18.70 (up 18 cents at the midpoint) and revenue growth to 5.9%-6.7% (up 50 bps at the midpoint).
-
Third Acquisition Signed: Millennium Health
Subsequent to quarter end Labcorp signed agreements for BioReference Health assets, Myriad Genetics' prenatal business, and Millennium Health, a specialty drug-testing lab; all are subject to regulatory approval and customary closing conditions.
-
Margin Expansion Despite CMS Rate Pressure
Adjusted operating margin rose 60 bps to 15.0% on organic growth and operating efficiencies, following the September CMS proposal to cut Medicare lab rates.
Analysis · LH · Industrial Applications And Services
Labcorp grew revenue 6.9% to $3.81 billion and adjusted EPS 14.5% to $4.78, then lifted full-year adjusted EPS guidance to $18.30-$18.70 — 18 cents higher at the midpoint — and revenue growth to 5.9%-6.7%. That matters because the raise comes just weeks after CMS proposed cutting Medicare lab payment rates, a $1B industry-wide reduction that had pressured the stock; delivering margin expansion (adjusted operating margin 15.0%, up 60 bps) alongside a guidance increase shows the core testing business is absorbing that threat for now. The company also signed a third acquisition, Millennium Health, adding to the BioReference and Myriad prenatal deals announced in October, and still has $1.4 billion left on its buyback authorization.
How filings like this one have moved
In the 30 days to Oct 28, 2026, 36.5% of the 953 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.66%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LH was trading at $335.99 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $26.9B. The 52-week trading range was $244.52 to $341.80. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.